The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

Its monotherapy drug that is used to treat desmoid tumors has been approved in the United States. A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

indicates confidence in the drug’s efficacy but still requires further data presentation for comprehensive evaluation. While the trial’s early success and Merck’s increased sales guidance ...